Vision - Conquer prostate cancer

Prostate Cancer Cover Image

Click on Image to View Program Booklet

Prostate cancer is the most commonly diagnosed cancer in men and is the second most common cause of male death from cancer. In 2016, approximately 180,890 men in the U.S. will be diagnosed with prostate cancer and an estimated 26,120 will die from it. In addition, there are major population disparities in prostate cancer incidence and mortality, with African American men experiencing 2.5 times greater risk of prostate cancer death compared to Caucasian men. The Prostate Cancer Research Program prioritizes research that will 1) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer, 2) develop strategies to prevent progression to lethal prostate cancer, 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer, and 4) develop strategies to optimize the physical and mental health of men with prostate cancer. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.

Congressional Appropriations

Congressional Appropriations

  • $1.45 billion
  • $80.0 million

PCRP Perspectives

PCRP Perspectives: Keep Informed on Breakthroughs in Prostate Cancer Research

Innovative Minds

Innovative Minds in Prostate Cancer Today

The IMPaCT 2011 Conference was held March 9-12, 2011 in Orlando, Florida. Click here for more information.

Related Videos

Dr. Colin Pritchard

University of Washington
Hypermutation and Genomic Testing for Precision Therapy in Advanced Prostate Cancer

Dr. Himisha Beltran

Weill Cornell Medicine
Divergent Clonal Evolution of Castration Resistant Neuroendocrine Prostate Cancer

Dr. John Kurhanewicz

University of California, San Francisco
Hyperpolarized Molecular Imaging Biomarkers in a Novel Prostate Tissue Slice Culture Model

Last updated Friday, April 21, 2017